Related Experiment Video
Updated: Jun 16, 2025
13:35
Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
2.5K
Breast reconstruction with TiLOOP® Bra: Another arrow in plastic surgeons' quiver?
Annachiara Tellarini1, Elisa Bascialla1, Ferruccio Paganini1
1Division of Plastic and Reconstructive Surgery, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS
|August 16, 2024
Summary
TiLOOP® Bra offers a safe and effective alternative to Acellular Dermal Matrices for immediate breast reconstruction after mastectomy, showing comparable seroma rates and benefits in radiated patients.
Area of Science:
- Plastic Surgery
- Oncology
- Biomaterials
Background:
- Immediate breast reconstruction is feasible with lower-pole sling products.
- Limited comparative data exists for biological vs. synthetic meshes in breast reconstruction complications.
Purpose of the Study:
- To compare the efficacy and safety of TiLOOP® Bra (Titanium-Coated Polypropylene Mesh) with Acellular Dermal Matrices (ADMs) for immediate breast reconstruction.
- To evaluate postoperative complications and patient outcomes.
Main Methods:
- Systematic literature search across PubMed, Web of Science, and Embase.
- Keywords: "breast reconstruction", "TiLOOP®", "Titanium-Coated Polypropylene Mesh", "TCPM".
- Analysis of perioperative characteristics, complications, and patient-reported outcomes.
Main Results:
- 41 studies including 3923 patients and 5042 breasts met inclusion criteria.
- TiLOOP® Bra is a safe and aesthetically valid alternative to ADMs in non-smokers.
- Complications are more likely in patients with extreme BMI.
Conclusions:
- TiLOOP® Bra demonstrates comparable seroma incidence to ADMs.
- It shows benefits in radiated patients, potentially superior to implant-only reconstruction.
- Good bio-integration and infection resistance observed, even in immunocompromised patients.
